2026-05-07 share offering or dilution eventrecentOpen filing ↗ “…fiscal years. The Company prospectively adopted ASU 2024-04 as of January 1, 2026. The adoption did not have a material impact on…”
+1 more passage from the same document
- “…are generally secured by first priority liens over substantially all of the assets of each of Lantheus Medical, Lantheus Holdings,…”
2026-05-07 capital return (buybacks/dividends)recentOpen filing ↗ “…and commercialize Lantheus’ piflufolastat F-18 PET imaging agent (marketed in the United States as PYLARIFY) in Japan for…”
+1 more passage from the same document
- “…and commercialize Lantheus’ piflufolastat F-18 PET imaging agent (marketed in the United States as PYLARIFY) in Japan for prostate…”
2026-05-07 merger or acquisition eventrecentOpen filing ↗ “…consolidated financial statements herein. Acquisition of Evergreen Theragnostics, Inc. On April 1, 2025, we acquired all the…”
+1 more passage from the same document
- “…Acquisition of Evergreen Theragnostics, Inc. On April 1, 2025, we acquired all the issued and outstanding shares of Evergreen by…”
2026-05-07 reverse splitrecentOpen filing ↗ “…tumors, and an option to co-develop certain early-stage therapeutic candidates targeting prostate cancer using…”
+1 more passage from the same document
- “…of neuroendocrine tumors, and an option to co-develop certain early-stage therapeutic candidates targeting prostate cancer using…”
2026-02-26 share offering or dilution eventrecentOpen filing ↗ “…or prevent a decrease in, the market price of our common stock, although there can be no assurance that an increase, or prevention of…”
+1 more passage from the same document
- “…in a different manner, which could negatively impact the market price of our common stock. The conditional conversion feature…”
2026-02-26 capital return (buybacks/dividends)recentOpen filing ↗ “…and PMF sites to ensure a smooth rollout of the new formulation, including providing clear guidance on ordering, handling, and…”
+1 more passage from the same document
- “…and PMF sites to ensure a smooth rollout of the new formulation, including providing clear guidance on ordering, handling, and…”
2026-02-26 merger or acquisition eventrecentOpen filing ↗ “…Life Molecular to Lantheus Biosciences Ltd. Acquisition of Evergreen Theragnostics, Inc. On April 1, 2025, we acquired all the…”
+1 more passage from the same document
- “…Acquisition of Evergreen Theragnostics, Inc. On April 1, 2025, we acquired all the issued and outstanding shares of Evergreen by…”
2026-02-26 reverse splitrecentOpen filing ↗ “…to Perspective, and the parties entered into a transition services arrangement pursuant to which we provided to Perspective…”
+1 more passage from the same document
- “…to Perspective, and the parties entered into a transition services arrangement pursuant to which we provided to Perspective…”
Recorded SEC filings in plain language — not advice or a prediction.
